Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.48M Sell
36,858
-48
-0.1% -$3.2K 0.36% 62
2026
Q1
$2.32M Buy
36,906
+30,150
+446% +$2.1M 0.37% 62
2025
Q4
$448K Sell
6,756
-1,200
-15% -$77.6K 0.07% 253
2025
Q3
$535K Sell
7,956
-593
-7% -$46.9K 0.07% 240
2025
Q2
$746K Sell
8,549
-10,979
-56% -$861K 0.1% 172
2025
Q1
$1.33M Buy
19,528
+1,292
+7% +$105K 0.24% 98
2024
Q4
$1.42M Buy
18,236
+7,373
+68% +$546K 0.25% 95
2024
Q3
$728K Buy
10,863
+1,047
+11% +$86K 0.13% 155
2024
Q2
$1.11M Sell
9,816
-1,214
-11% -$153K 0.23% 97
2024
Q1
$1.53M Buy
11,030
+320
+3% +$40.2K 0.32% 81
2023
Q4
$1.33M Sell
10,710
-1,750
-14% -$179K 0.3% 85
2023
Q3
$1.16M Buy
12,460
+1,290
+12% +$145K 0.29% 89
2023
Q2
$1.44M Buy
11,170
+220
+2% +$26.6K 0.34% 73
2023
Q1
$1.27M Buy
10,950
+690
+7% +$77.2K 0.32% 84
2022
Q4
$1.16M Hold
10,260
0.29% 91
2022
Q3
$826K Hold
10,260
0.21% 121
2022
Q2
$765K Sell
10,260
-3,900
-28% -$356K 0.19% 124
2022
Q1
$1.81M Sell
14,160
-100
-0.7% -$10.9K 0.39% 71
2021
Q4
$1.91M Hold
14,260
0.38% 73
2021
Q3
$1.95M Buy
14,260
+3,756
+36% +$474K 0.43% 63
2021
Q2
$1.12M Buy
+10,504
New +$1.01M 0.27% 105

Other funds holding DXCM

Chicago Trust's DXCM Position: Q2 2026 in Review

Chicago Trust reduced its DexCom (DXCM) stake by 0.13% in Q2 2026, selling an estimated $3.2K and leaving 36,858 shares worth $2.48M. The position accounts for 0.36% of the portfolio, ranked #62.

Chicago Trust first reported a position in DXCM in Q2 2021 and has held it in 21 quarters since. 147 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

  • Chicago Trust held 36,858 shares of DexCom worth $2.48M as of Q2 2026.
  • Chicago Trust sold 48 DexCom shares in Q2 2026, an estimated $3.2K.
  • DexCom made up 0.36% of Chicago Trust's portfolio in Q2 2026, its #62 holding.
  • Chicago Trust first reported a position in DexCom in Q2 2021 and has held it in 21 quarters since.
  • 147 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on Chicago Trust's 13F filing for Q2 2026, filed 16 Jul 2026.